{
  "id": "primary-myelofibrosis",
  "title": "Primary Myelofibrosis",
  "lang": "en",
  "source_lang": "en",
  "summary": "Primary myelofibrosis is a chronic blood cancer characterized by abnormal blood-cell production, progressive marrow fibrosis, and a variable risk of transformation to acute leukemia.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "PMF",
    "Chronic idiopathic myelofibrosis",
    "Agnogenic myeloid metaplasia",
    "Myelofibrosis with myeloid metaplasia"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/primary-myelofibrosis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/primary-myelofibrosis/",
      "json": "https://aiwiki.page/zh/primary-myelofibrosis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm in which an abnormal clone of blood-forming stem cells produces disordered blood-cell development and, typically, progressive scarring of the bone marrow. It can cause anemia, enlargement of the spleen, constitutional symptoms, and abnormal blood counts. The disease ranges from an early, prefibrotic phase to overt fibrotic disease and may transform into acute myeloid leukemia."
    },
    {
      "heading": "Classification and terminology",
      "text": "PMF belongs to the group of BCR::ABL1-negative myeloproliferative neoplasms, alongside polycythemia vera and essential thrombocythemia. These disorders originate in blood-forming cells but differ in their predominant blood-count abnormalities and marrow features.\n\n“Primary” distinguishes PMF from myelofibrosis that develops after established polycythemia vera or essential thrombocythemia. Those conditions are called post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Marrow scarring can also occur in other malignant and nonmalignant disorders; fibrosis alone does not establish a diagnosis of PMF.\n\nModern classifications distinguish two forms:\n\n- Prefibrotic or early PMF: characteristic abnormalities of marrow megakaryocytes and increased cellularity, with absent or only mild reticulin fibrosis.\n- Overt fibrotic PMF: characteristic megakaryocyte abnormalities accompanied by more substantial reticulin or collagen fibrosis.\n\nOlder names such as agnogenic myeloid metaplasia occur in historical literature but are less precise than the current terminology."
    },
    {
      "heading": "Biological basis",
      "text": "PMF develops through acquired genetic changes in a hematopoietic stem cell. Most patients have a driver mutation affecting JAK2, CALR, or MPL. These alterations promote abnormal activation of the JAK–STAT signaling pathway, which regulates blood-cell production and responses to growth factors. A minority of cases lack detectable mutations in all three genes and are described as triple-negative.\n\nAdditional mutations affecting epigenetic regulation, RNA splicing, and other cellular processes can influence disease behavior. PMF is generally an acquired disorder rather than a directly inherited disease, although familial susceptibility to myeloproliferative neoplasms exists.\n\nThe marrow fibrosis is largely a reactive response to signals released by abnormal blood-forming cells, particularly megakaryocytes, rather than a primary cancer of the connective tissue itself. These signals stimulate stromal cells to deposit reticulin and collagen. Inflammatory signaling also contributes to systemic symptoms.\n\nAs effective marrow blood formation becomes impaired, blood-cell production may expand in sites outside the marrow, especially the spleen and liver. This process is called extramedullary hematopoiesis."
    },
    {
      "heading": "Epidemiology and clinical features",
      "text": "PMF is rare and occurs predominantly in older adults, although younger adults can also be affected. Estimates of its frequency vary across populations and according to diagnostic criteria.\n\nSome cases are discovered incidentally through an abnormal complete blood count. Others present with manifestations of ineffective blood formation, splenic enlargement, or systemic inflammation.\n\nCommon findings include:\n\n- Anemia, which may cause tiredness, weakness, or reduced exercise tolerance.\n- An enlarged spleen, sometimes producing abdominal discomfort or early satiety.\n- Night sweats, unintentional weight loss, fever, and itching.\n- Increased or decreased white-cell and platelet counts, depending on disease phase.\n- Easy bruising or bleeding, particularly when platelet numbers or function are impaired.\n\nA peripheral blood film may show teardrop-shaped red cells, immature granulocytes, and nucleated red cells. The combination of immature myeloid cells and nucleated red cells is termed a leukoerythroblastic blood picture. It is characteristic of overt disease but is not specific to PMF.\n\nComplications include severe cytopenias, infection, bleeding, thrombosis, portal hypertension, and symptomatic extramedullary hematopoiesis. A proportion of patients develop an accelerated or blast phase; a blast proportion of at least 20% in blood or marrow defines blast-phase disease."
    },
    {
      "heading": "Diagnosis",
      "text": "Diagnosis integrates clinical findings, blood tests, molecular testing, and marrow morphology. No single symptom, mutation, or fibrosis finding is sufficient by itself.\n\nBone marrow examination\n\nA marrow biopsy is central to classification. It assesses cellularity, megakaryocyte distribution and appearance, other blood-forming cell lineages, and the degree of fibrosis. Megakaryocytes typically show abnormal nuclear maturation and clustering.\n\nIn advanced fibrosis, aspiration may yield little or no material—a “dry tap”—making the core biopsy particularly important. Fibrosis is commonly graded on a scale from MF-0 to MF-3. Prefibrotic PMF has no more than grade 1 fibrosis, whereas overt fibrotic PMF generally has grade 2 or 3 fibrosis.\n\nMolecular and supporting findings\n\nTesting usually includes JAK2, CALR, and MPL. Broader genetic testing can identify other evidence of clonality and mutations relevant to prognosis. Chromosome analysis provides additional diagnostic and prognostic information.\n\nSupporting findings include unexplained anemia, leukocytosis, splenic enlargement, and increased lactate dehydrogenase. A leukoerythroblastic blood picture is particularly relevant in overt fibrotic disease. Formal criteria combine defined marrow and molecular findings with specified clinical or laboratory features.\n\nDifferential diagnosis\n\nThe differential diagnosis includes other myeloproliferative neoplasms, chronic myeloid leukemia, myelodysplastic syndromes, and reactive or secondary causes of marrow fibrosis.\n\nDistinguishing prefibrotic PMF from essential thrombocythemia is especially important because both can present with a high platelet count. Interpretation depends substantially on marrow morphology in its clinical and molecular context."
    },
    {
      "heading": "Prognosis and disease assessment",
      "text": "The clinical course is highly variable. Some patients remain stable for many years, while others develop progressive marrow failure, severe symptoms, or leukemic transformation over a shorter period. A single survival estimate therefore does not adequately describe the disease.\n\nPrognostic systems incorporate different combinations of:\n\n- Age and constitutional symptoms.\n- Hemoglobin concentration, white-cell count, and circulating blasts.\n- Platelet count and dependence on red-cell transfusions.\n- Chromosomal abnormalities.\n- Driver mutation status and additional adverse molecular findings.\n\nEstablished systems include the International Prognostic Scoring System, its dynamic versions, and mutation- or genetics-based models such as MIPSS70 and GIPSS. These models have different intended settings and are not interchangeable. Prognostic risk also differs from symptom burden: marked symptoms can occur without the highest predicted risk of death or leukemic transformation."
    },
    {
      "heading": "Treatment",
      "text": "Treatment is individualized according to disease risk, symptoms, blood counts, transfusion requirements, coexisting conditions, and transplant eligibility. Its goals may include symptom control, reduction of splenic enlargement, management of anemia, or long-term disease eradication.\n\nObservation and supportive treatment\n\nPeople with lower-risk disease and few symptoms may undergo observation with periodic reassessment rather than immediate drug treatment.\n\nAnemia management can include red-cell transfusion and, in selected circumstances, erythropoiesis-stimulating agents, danazol, or other anemia-directed treatments. Responses vary with the biological cause of anemia and the stage of disease. Hydroxyurea can reduce excessive blood counts or splenic enlargement in some patients.\n\nJAK inhibitors\n\nJAK inhibitors are an important form of targeted therapy for symptomatic myelofibrosis. Drugs used in relevant clinical settings include ruxolitinib, fedratinib, pacritinib, and momelotinib. Their regulatory indications and availability vary by jurisdiction.\n\nThese agents can reduce spleen size and improve constitutional symptoms. They differ in their effects on anemia, platelet counts, and other safety considerations. Their activity does not require a JAK2 mutation, because abnormal signaling can occur through several molecular mechanisms.\n\nJAK inhibitors are not generally curative and do not reliably eliminate the malignant clone. Treatment effects on symptoms, blood counts, fibrosis, and survival are distinct outcomes and should not be treated as equivalent.\n\nStem-cell transplantation\n\nAllogeneic hematopoietic stem-cell transplantation is the only established treatment with curative potential. Donor-derived blood formation and immune activity against the abnormal clone can produce durable remission.\n\nTransplantation also carries substantial risks, including infection, organ toxicity, graft-versus-host disease, relapse, and treatment-related death. Eligibility and timing depend on disease risk, physiological fitness, donor availability, and the expected balance between disease-related and transplant-related risks.\n\nOther interventions, including splenic irradiation or splenectomy, have limited roles in selected cases because their benefits must be weighed against significant complications."
    }
  ],
  "links": [
    "bone-marrow",
    "anemia",
    "acute-myeloid-leukemia",
    "mutation",
    "jak-stat-signaling-pathway",
    "fibrosis",
    "spleen",
    "extramedullary-hematopoiesis",
    "complete-blood-count",
    "thrombosis",
    "diagnosis",
    "biopsy",
    "differential-diagnosis",
    "chronic-myeloid-leukemia",
    "myelodysplastic-syndrome",
    "blood-transfusion",
    "hydroxyurea",
    "targeted-cancer-therapy",
    "hematopoietic-stem-cell-transplantation",
    "graft-versus-host-disease"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}